Dr. Michael E. Mendelsohn, MD, is an Independent Director at Cyclerion Therapeutics, Inc., an Independent Director at Foghorn Therapeutics, Inc., a Chairman at Cardurion Pharmaceuticals LLC, a Chief Medical & Scientific Officer at Takeda Pharmaceutical Co., Ltd. and a President at Mendelsohn Consulting Group LLC. He is on the Board of Directors at Cyclerion Therapeutics, Inc. and Foghorn Therapeutics, Inc. Dr. Mendelsohn was previously employed as a President & Chief Scientific Officer by Ironwood Pharmaceuticals, Inc., a Venture Partner by SV Life Sciences Managers LLP, an Independent Director by Regado Biosciences, Inc., a Senior VP & Global Head-Cardiovascular Research by Merck Research Laboratories Massachusetts LLC, an Executive Director-MCRI by Tufts Medical Center, Inc., and a Chief Scientific Officer by Tufts University School of Medicine. He received his undergraduate degree from Amherst College and a doctorate degree from Harvard Medical School.